GeoVax Labs, a clinical-stage biotechnology company, will present its Mpox vaccine program at the Emerging Growth Conference on February 19, 2025. CEO David Dodd will deliver a presentation focused on the development of GEO-MVA, the company's vaccine candidate targeting Mpox and smallpox.
The live, interactive online event provides an opportunity for shareholders and investment professionals to gain insights into the company's infectious disease research. Dodd will present at 2:55 pm ET and will subsequently participate in a question-and-answer session, allowing attendees to explore the potential of the Mpox vaccine candidate.
This presentation comes at a critical time as infectious disease prevention remains a global health priority. By developing targeted vaccine solutions for diseases like Mpox, GeoVax continues to contribute to potential medical advancements in preventing and controlling infectious diseases.
The conference presentation represents an important platform for GeoVax to communicate its scientific progress and strategic vision to investors and the broader scientific community. For those unable to attend the live event, an archived webcast will be made available through the conference's online channels.
